226 related articles for article (PubMed ID: 21760507)
1. Current management of lymphangioleiomyomatosis.
Taillé C; Borie R; Crestani B
Curr Opin Pulm Med; 2011 Sep; 17(5):374-8. PubMed ID: 21760507
[TBL] [Abstract][Full Text] [Related]
2. Lymphangioleiomyomatosis treatment with sirolimus.
Casanova A; María Girón R; Acosta O; Barrón M; Valenzuela C; Ancochea J
Arch Bronconeumol; 2011 Sep; 47(9):470-2. PubMed ID: 21440356
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
Goncharova EA; Krymskaya VP
J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
[TBL] [Abstract][Full Text] [Related]
5. Sirolimus treatment for recurrent lymphangioleiomyomatosis after lung transplantation.
Chen F; Omasa M; Kondo N; Fujinaga T; Shoji T; Sakai H; Bando T
Ann Thorac Surg; 2009 Jan; 87(1):e6-7. PubMed ID: 19101258
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.
Davies DM; de Vries PJ; Johnson SR; McCartney DL; Cox JA; Serra AL; Watson PC; Howe CJ; Doyle T; Pointon K; Cross JJ; Tattersfield AE; Kingswood JC; Sampson JR
Clin Cancer Res; 2011 Jun; 17(12):4071-81. PubMed ID: 21525172
[TBL] [Abstract][Full Text] [Related]
7. Chyloperitoneum, chylothorax and lower extremity lymphedema in woman with sporadic lymphangioleiomyomatosis successfully treated with sirolimus: a case report.
Chachaj A; Drozdz K; Chabowski M; Dziegiel P; Grzegorek I; Wojnar A; Jazwiec P; Szuba A
Lymphology; 2012 Jun; 45(2):53-7. PubMed ID: 23057149
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report.
Ito T; Suno M; Sakamoto K; Yoshizaki Y; Yamamoto K; Nakanishi R; Hirano Y; Irie M; Kurosaki T; Otani S; Yamane M; Sugimoto S; Miyoshi K; Oto T
Transplant Proc; 2016; 48(1):271-4. PubMed ID: 26915883
[TBL] [Abstract][Full Text] [Related]
9. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
El-Chemaly S; Goldberg HJ; Glanville AR
Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
[TBL] [Abstract][Full Text] [Related]
10. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells.
Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP
Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246
[TBL] [Abstract][Full Text] [Related]
11. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
[TBL] [Abstract][Full Text] [Related]
12. The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials.
El-Chemaly S; Henske EP
Expert Rev Respir Med; 2015 Apr; 9(2):195-204. PubMed ID: 25757365
[TBL] [Abstract][Full Text] [Related]
13. Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations.
Freitas CS; Baldi BG; Araújo MS; Heiden GI; Kairalla RA; Carvalho CR
J Bras Pneumol; 2015; 41(3):275-80. PubMed ID: 26176526
[TBL] [Abstract][Full Text] [Related]
14. CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis.
Glasgow CG; Pacheco-Rodriguez G; Steagall WK; Haughey ME; Julien-Williams PA; Stylianou MP; Gochuico BR; Moss J
Chest; 2018 Feb; 153(2):339-348. PubMed ID: 28576630
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis.
Cai X; Pacheco-Rodriguez G; Haughey M; Samsel L; Xu S; Wu HP; McCoy JP; Stylianou M; Darling TN; Moss J
Chest; 2014 Jan; 145(1):108-112. PubMed ID: 24051985
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis.
Wang Q; Luo M; Xiang B; Chen S; Ji Y
Respir Res; 2020 Feb; 21(1):55. PubMed ID: 32059669
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation.
Sugimoto R; Nakao A; Yamane M; Toyooka S; Okazaki M; Aoe M; Seyama K; Date H; Oto T; Sano Y
J Heart Lung Transplant; 2008 Aug; 27(8):921-4. PubMed ID: 18656809
[TBL] [Abstract][Full Text] [Related]
18. SUCCESSFUL TREATMENT OF PULMONARY AND LYMPHATIC MANIFESTATIONS OF LYMPHANGIOLEIOMYOMATOSIS WITH SIROLIMUS.
Hecimovic A; Jakopovic M; Pavlisa G; Jankovic M; Vukic-Dugac A; Redzepi G; Brcic L; Samarzija M; Gupta N
Lymphology; 2015 Jun; 48(2):97-102. PubMed ID: 26714374
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review.
Peng ZF; Yang L; Wang TT; Han P; Liu ZH; Wei Q
J Urol; 2014 Nov; 192(5):1424-30. PubMed ID: 24813310
[TBL] [Abstract][Full Text] [Related]
20. Lymphangioleiomyomatosis: Current understanding and potential treatments.
Moir LM
Pharmacol Ther; 2016 Feb; 158():114-24. PubMed ID: 26713679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
